European Union - English - EMA (European Medicines Agency)

novartis europharm ltd - valsartan, amlodipine (as amlodipine besilate) - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension.imprida is indicated in patients whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.

European Union - English - EMA (European Medicines Agency)

novartis europharm ltd - aliskiren, amlodipine - hypertension - agents acting on the renin-angiotensin system - rasilamlo is indicated for the treatment of essential hypertension in adult patients whose blood pressure is not adequately controlled with aliskiren or amlodipine used alone.

European Union - English - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren, hydrochlorothiazide - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension in adults.riprazo hct is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone.rirpozo hct is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.

European Union - English - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren, hydrochlorothiazide - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension in adults.sprimeo hct is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone.sprimeo hct is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.

European Union - English - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension.

European Union - English - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension.

European Union - English - EMA (European Medicines Agency)

novartis europharm limited - basiliximab - graft rejection; kidney transplantation - immunosuppressants - simulect is indicated for the prophylaxis of acute organ rejection in de-novo allogeneic renal transplantation in adult and paediatric patients (1-17 years).it is to be used concomitantly with ciclosporin for microemulsion- and corticosteroid-based immunosuppression, in patients with panel reactive antibodies less than 80%, or in a triple maintenance immunosuppressive regimen containing ciclosporin for microemulsion, corticosteroids and either azathioprine or mycophenolate mofetil.

European Union - English - myHealthbox

novartis europharm limited - indacaterol, glycopyrronium bromide - inhalation powder, hard capsule - 110 microgram indacaterol and 50 microgram glycopyrronium - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, adrenergics in combination with anticholinergics - indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd)

European Union - English - myHealthbox

novartis europharm limited - indacaterol, glycopyrronium - inhalation powder, hard capsule - 85 micrograms/43 micrograms - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, adrenergics in combination with anticholinergics - indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd)

European Union - English - EMA (European Medicines Agency)

novartis europharm ltd - ofatumumab - leukemia, lymphocytic, chronic, b-cell - monoclonal antibodies - previously untreated chronic lymphocytic leukaemia (cll): arzerra in combination with chlorambucil or bendamustine is indicated for the treatment of patients with cll who have not received prior therapy and who are not eligible for fludarabine-based therapy. relapsed cll: arzerra is indicated in combination with fludarabine and cyclophosphamide for the treatment of adult patients with relapsed cll. refractory cll: arzerra is indicated for the treatment of cll in patients who are refractory to fludarabine and alemtuzumab.,